Our news journalists obtained a quote from the research from Beth Israel Deaconess Medical Center, "Efforts to improve survival outcomes with gemcitabine-based combination chemotherapy regimens have been largely disappointing, with the possible exception of the addition of the targeted agent erlotinib. The multi-agent cytotoxic chemotherapy regimen FOLFIRINOX (sequential administration of oxaliplatin immediately followed by leucovorin over 2 hours, and then irinotecan, followed by a bolus dose of 5-fluorouracil, and finally, a 46-hour infusion of 5-fluorouracil) has significantly improved survival compared with gemcitabine alone; however, this regimen can be highly toxic and may need to be reserved for those with an excellent performance status. This article reviews the existing evidence for the management of patients with metastatic pancreatic cancer with chemotherapy with special attention to careful patient selection. The data for chemotherapy combined with targeted therapy are discussed."
According to the news editors, the research concluded: "Additional supportive modalities in the areas of pharmacologic and nutritional support to maximize quality of life are also outlined."
For more information on this research see: Chemotherapy and Other Supportive Modalities in the Palliative Setting for Pancreatic Cancer. Cancer Journal, 2012;18(6):633-641. Cancer Journal can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA.
Our news journalists report that additional information may be obtained by contacting K.M. Sullivan, Beth Israel Deaconess Med Center, New York, NY 10003, United States.
Keywords for this news article include: Antimetabolites, Antineoplastics, Antivirals, Drugs, Therapy, Oncology, Gemcitabine, New York City, United States, Gastroenterology, Pancreatic Cancer, Pancreatic Neoplasms, Immunosuppressive Agents, North and Central America, Radiation-Sensitizing Agents
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.